新一批医药标的3月“圆梦进通”

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical sector [4] Core Insights - The pharmaceutical sector is experiencing a rebound due to the recognition of its importance as a pillar industry during the Two Sessions, alongside specific market events that have positively influenced certain stocks, particularly in innovative drugs and vitamin price increases [10][28] - The report emphasizes the importance of innovation and international expansion as key drivers for the pharmaceutical industry in 2026, with a focus on high-growth Q1 performance and strategic combinations of companies [10][21] - The report identifies specific companies to watch, including KJ Pharmaceuticals, Weili Zhibo-B, and others, highlighting their innovative drug pipelines and potential for growth [10][13][22] Summary by Sections 1. Newly Included Hong Kong Stock Connect Pharmaceutical Targets - The report outlines the new pharmaceutical targets included in the Hong Kong Stock Connect for March 2026, which are expected to benefit from improved liquidity and valuation [13] - Key companies include: - InSilico Medicine: Focused on AI drug discovery with promising clinical pipelines [13][17] - KJ Pharmaceuticals: Leading in CAR-T cell therapy for solid tumors [18][21] - Weili Zhibo: Developing multi-mechanism immunotherapy for tumors [22] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical index decreased by 2.78% from March 2 to March 6, underperforming compared to the ChiNext and CSI 300 indices [28] - The report notes that the pharmaceutical sector has been in a state of recovery, with specific stocks showing significant rebounds due to market dynamics [10][28] - The report highlights the trading volume in the pharmaceutical sector, which accounted for 3.40% of the total market turnover, below the historical average of 7.08% [47] 3. Industry Valuation and Performance - The current PE ratio for the pharmaceutical sector is 30.48X, which is below the historical average of 35.85X, indicating a relative undervaluation [46] - The report notes that the valuation premium of the pharmaceutical sector compared to the A-share market is at a low level, suggesting potential for future growth [46][48]